EOJOAM
ALLO icon

E. Ohman J:or Asset Management’s Allogene Therapeutics ALLO Stock Holding History

E. Ohman J:or Asset Management’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-7,400
Closed -$144K – 431
2020
Q1 		$144K Buy
7,400
+400
+6% +$9.53K 0.01% 397
2019
Q4 		$182K Buy
+7,000
New +$193K 0.01% 420

Other funds holding ALLO

TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VM
VV Manager Boston, Massachusetts $114M AUM 59.16% 1-Year Est. Return

E. Ohman J:or Asset Management's ALLO Position: Q2 2020 in Review

E. Ohman J:or Asset Management sold out of Allogene Therapeutics (ALLO) in Q2 2020, closing a stake of 7,400 shares — an estimated $144K sold.

E. Ohman J:or Asset Management first reported a position in ALLO in Q4 2019 and held it in 2 quarters. The position peaked at $182K in Q4 2019. 173 funds tracked by Wall St. Rank hold ALLO as of Q2 2020.

  • E. Ohman J:or Asset Management reported no remaining Allogene Therapeutics position as of Q2 2020 after selling out during the quarter.
  • E. Ohman J:or Asset Management sold 7,400 Allogene Therapeutics shares in Q2 2020, an estimated $144K.
  • E. Ohman J:or Asset Management first reported a position in Allogene Therapeutics in Q4 2019 and held it in 2 quarters.
  • E. Ohman J:or Asset Management's Allogene Therapeutics position peaked at $182K in Q4 2019.
  • 173 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2020.

Based on E. Ohman J:or Asset Management's 13F filing for Q2 2020, filed 5 Apr 2024.